Price movement over the last 24 hours
AbCellera Biologics Inc vs Teucrium Corn Fund — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while Teucrium Corn Fund trades at $17.4. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| ABCL | CORN | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $8.12 | $19.12 |
52-Week Low | $2.78 | $16.46 |
Enterprise Value | $1.99B | — |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CORN stock trades at $17.45, up 3.5% today, with a bullish technical signal from moving averages and oscillators. Key support is at $17 and resistance at $18. Recent news includes a licensing partnership with Hormel Foods for CORN NUTS® brands (GlobeNewsWire, 2026-05-07).
The outlook is cautiously optimistic given technical momentum, but fundamental data is unavailable. Risks include reliance on brand licensing and broader market volatility. Investors should monitor upcoming earnings for financial health indicators.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →